Search for content, post, videos

Lundbeck Alcohol Addiction Drug Wins Approval in UK

Just two days after the Danish company’s Lundbeck CEO stepped down for an ethics lapse, the UK’s National Institute for Health and Care Excellence (NICE) gave Selincro (namelfene) approval in final draft guidance, meaning the country’s National Health Service will make funding available for the £42.42-per-14-tablet-pack medication within three months.

“We are pleased to be able to recommend the use of namelfene to support people further in their efforts to fight alcohol dependence,” NICE Health Technology Evaluation Centre Director Carole Longson said in a statement. “When used alongside psychosocial support, nalmefene is clinically and cost effective for the NHS compared with psychosocial support alone.”

The latest reimbursement decision should reach about 600,000 alcohol-addicted individuals in England and Wales, according to Lundbeck partner Biotie Therapies, and it follows similar decisions from countries like France and Spain.